Stonebridge Capital Advisors LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,999 shares of the company’s stock after purchasing an additional 3,606 shares during the period. Johnson & Johnson comprises about 1.4% of Stonebridge Capital Advisors LLC’s investment portfolio, making the stock its 18th biggest position. Stonebridge Capital Advisors LLC’s holdings in Johnson & Johnson were worth $12,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Steward Financial Group LLC acquired a new stake in Johnson & Johnson in the 4th quarter worth $34,000. Iron Horse Wealth Management LLC grew its position in Johnson & Johnson by 29.9% in the 4th quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. grew its position in Johnson & Johnson by 290.7% in the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 293 shares of the company’s stock worth $47,000 after purchasing an additional 218 shares during the last quarter. Retirement Group LLC grew its position in Johnson & Johnson by 20.5% in the 4th quarter. Retirement Group LLC now owns 447 shares of the company’s stock worth $77,000 after purchasing an additional 76 shares during the last quarter. Finally, Bell Investment Advisors Inc bought a new position in shares of Johnson & Johnson during the 3rd quarter worth about $76,000. Institutional investors own 68.78% of the company’s stock.
In other news, VP Thibaut Mongon sold 23,681 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, March 17th. The shares were sold at an average price of $176.25, for a total transaction of $4,173,776.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider William Hait sold 29,699 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the sale, the insider now owns 80,236 shares of the company’s stock, valued at approximately $14,729,724.88. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.
Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The company had revenue of $23.43 billion during the quarter, compared to the consensus estimate of $23.62 billion. During the same period in the previous year, the firm posted $2.59 earnings per share. The company’s revenue was up 5.0% on a year-over-year basis. Equities analysts anticipate that Johnson & Johnson will post 10.2 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 7th. Shareholders of record on Tuesday, May 24th will be paid a $1.13 dividend. The ex-dividend date is Monday, May 23rd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.50%. Johnson & Johnson’s payout ratio is currently 60.92%.
JNJ has been the subject of a number of analyst reports. Raymond James raised their price objective on shares of Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a report on Wednesday, April 20th. Citigroup reduced their price objective on shares of Johnson & Johnson from $210.00 to $205.00 in a report on Tuesday, May 17th. Morgan Stanley reduced their price objective on shares of Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating for the company in a report on Wednesday, April 6th. Sanford C. Bernstein downgraded shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price objective for the stock from $180.00 to $183.00 in a report on Wednesday, March 16th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $187.86.
Johnson & Johnson Company Profile (Get Rating)
Johnson & Johnson researches and develops, manufactures, and sells various products in the healthcare field worldwide. It operates in three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- These Are the Three (3) Most Upgraded Stocks For Q2
- MarketBeat: Week in Review 5/23 – 5/27
- Short Sellers Provide Entry Into Hibbet, Inc At Rock Bottom Prices
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.